Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain pill could replace opioids after surgery

NCT ID NCT06887959

Symptom relief Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new painkiller called suzetrigine (Journavx) in 47 adults who had laparoscopic or arthroscopic surgery. The goal was to see if it works well and is safe as part of a combination of pain treatments. Participants took the tablet by mouth, and the study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
suzetrigine (also called VX-548 or Journavx), a pain-relief tablet
What this could lead to
If it works, this could offer a new non-opioid option for managing short-term pain after common surgeries, potentially reducing reliance on opioids.
What could go wrong
This is a small, completed Phase 4 study with only 47 participants. Results are not yet reported, and effectiveness in real-world settings may differ. Pain relief varies by individual.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

47 people

The number who actually took part.

Started

Mar 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2) * Scheduled to undergo a procedure that is in one of the following categories that would typically be treated with opioid therapy for at least 72 hours postoperatively such as * Laparoscopic intraperitoneal or retroperitoneal procedure * Arthroscopic orthopedic procedure Key Exclusion Criteria: -Participated in previous study with Suzetrigine or received Journavx Other protocol defined Inclusion/Exclusion criteria will apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain

Contacts and locations

Locations

  • Cooper University HealthCare (CUH)

    Camden, New Jersey, 08103, United States

  • Duke University Hospital - Anesthesiology

    Durham, North Carolina, 27710, United States

  • Eximia Research-Durham

    Durham, North Carolina, 27704, United States

  • Gulfcoast Research Institute

    Sarasota, Florida, 34232, United States

  • HD Research LLC | First Surgical Hospital

    Bellaire, Texas, 77401, United States

  • MedStar

    Baltimore, Maryland, 21218, United States

  • Memorial Hermann Village

    Houston, Texas, 77043, United States

  • North Shore University Hospital - Anesthesiology

    Manhasset, New York, 11030, United States

  • Oasis Clinical Research

    Las Vegas, Nevada, 89121, United States

  • OrthoCarolina - Hip & Knee Center

    Charlotte, North Carolina, 28207, United States

  • Scottsdale Clinical Trials

    Scottsdale, Arizona, 85260, United States

  • Seaside Clinical Research Institute

    Wilmington, North Carolina, 28412, United States

  • Tidewater Clinical Research

    Norfolk, Virginia, 23502, United States

  • UH Cleveland Medical Center - Anesthesiology

    Cleveland, Ohio, 44106, United States

  • University of Tennessee Medical Center - Anethesiology

    Knoxville, Tennessee, 37920, United States

  • West Clinical Research

    Morehead City, North Carolina, 28557, United States

  • Woodland International Research Group

    Little Rock, Arkansas, 72211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.